CervoMed is trading at $3.49, up 5.44% in pre-market versus its October 5 close of $3.31; no new company announcement explaining the move was identified.
- The price has also risen over recent sessions.
- The latest notable company news was the September 28 update on a new neflamapimod tablet and FDA removal of the prior drug-exposure limit; it does not establish a direct cause.
- Broader indexes are only modestly higher, offering limited evidence of a market-wide explanation.